文献速递胸部肿瘤放疗放疗物理与技术

动态肿瘤追踪立体定向体部放疗治疗肺部肿瘤安全性与疗效的多中心Ⅱ期研究

Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors.
PubMed 文献 · Radiother Oncol · 2022-05-02

这项多中心Ⅱ期研究纳入48例cStageⅠ期原发性肺癌或转移性肺癌且预期呼吸运动幅度≥10 mm的患者,采用万向架直线加速器实施动态肿瘤追踪立体定向体部放疗(DTT-SBRT),处方剂量50 Gy分4次。2年局部控制率为95.2%(单侧85%CI下限90.3%),2年总生存率79.2%(95%CI 64.7%-88.2%),2年无进展生存率75.0%(95%CI 60.2%-85.0%),仅1例(2.1%)出现3级放射性肺炎,未观察到4级或5级毒性。

要点

  • DTT-SBRT处方剂量50 Gy分4次,治疗中位呼吸运动幅度13.7 mm。
  • 2年局部控制率95.2%,单侧85%CI下限90.3%。
  • 仅1例(2.1%)发生3级放射性肺炎,无4级或5级毒性。

核心结论

  • DTT-SBRT在伴有呼吸运动的肺部肿瘤中取得了优异的局部控制率和较低的严重毒性发生率。

研究设计与样本

  • 多中心Ⅱ期研究,纳入48例cStageⅠ期原发性肺癌或转移性肺癌且预期呼吸运动幅度≥10 mm的患者,来自4家机构。
  • 处方剂量为50 Gy分4次,使用万向架直线加速器实施DTT-SBRT。
  • 主要终点为2年局部控制率。

主要发现

  • 48例患者中42例为原发性非小细胞肺癌,6例为转移性肺部肿瘤。
  • 47例患者的47个病灶接受了DTT-SBRT,中位每次治疗时间28分钟。
  • 治疗中位呼吸运动幅度为13.7 mm(范围4.5-28.1 mm)。
  • 1例患者因腹壁与肿瘤运动相关性差而采用运动包络法。
  • 中位随访32.3个月,2年局部控制率95.2%(单侧85%CI下限90.3%),2年总生存率79.2%(95%CI 64.7%-88.2%),2年无进展生存率75.0%(95%CI 60.2%-85.0%)。

关键数值与推荐

  • 入组条件为cStageⅠ期原发性肺癌或转移性肺癌且预期呼吸运动幅度≥10 mm。
  • 处方剂量为50 Gy分4次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study aimed to evaluate the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy (DTT-SBRT) for lung tumors. MATERIALS AND METHODS: Patients with cStage I primary lung cancer or metastatic lung cancer with an expected range of respiratory motion of ≥10 mm were eligible for the study. The prescribed dose was 50 Gy in four fractions. A gimbal-mounted linac was used for DTT-SBRT delivery. The primary endpoint was local control at 2 years. RESULTS: Forty-eight patients from four institutions were enrolled in this study. Forty-two patients had primary non-small-cell lung cancer, and six had metastatic lung tumors. DTT-SBRT was delivered for 47 lesions in 47 patients with a median treatment time of 28 min per fraction. The median respiratory motion during the treatment was 13.7 mm (range: 4.5-28.1 mm). The motion-encompassing method was applied for the one remaining patient due to the poor correlation between the abdominal wall and tumor movement. The median follow-up period was 32.3 months, and the local control at 2 years was 95.2% (lower limit of the one-sided 85% confidence interval [CI]: 90.3%). The overall survival and progression-free survival at 2 years were 79.2% (95% CI: 64.7%-88.2%) and 75.0% (95% CI: 60.2%-85.0%), respectively. Grade 3 toxicity was observed in one patient (2.1%) with radiation pneumonitis. Grade 4 or 5 toxicity was not observed. CONCLUSION: DTT-SBRT achieved excellent local control with low incidences of severe toxicities in lung tumors with respiratory motion.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo Y, Hiraoka M, Karasawa K, et al. Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors. Radiother Oncol. 2022. PMID: 35513131. doi:10.1016/j.radonc.2022.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。